Ivabradin 1 A Pharma (Ivabradine)

Ivabradine acts on the cardiac If current to lower heart rate, benefiting conditions where rate control improves outcomes.

• Chronic stable angina: improves exercise tolerance and reduces angina episodes.
• Heart failure with reduced ejection fraction: lowers hospitalization risk by decreasing heart rate.
• Symptomatic tachycardia when beta‑blockers are unsuitable: provides rate control without affecting contractility.

• Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows spontaneous depolarisation. This reduction in pacemaker activity lowers heart rate without compromising myocardial contractility, thereby decreasing myocardial oxygen demand while preserving cardiac output.

Ivabradine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Bradycardia: resting heart rate falls below 50 bpm.
• Visual disturbances (phosphenes): transient luminous phenomena.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Fatigue or weakness.
• Hypertension: occasional increase in blood pressure.

Serious or Rare Side Effects

• Severe bradycardia requiring medical intervention.
• Atrial fibrillation or other arrhythmias.
• Symptomatic hypotension.
• Persistent visual loss.
• Hepatic enzyme elevations.
• Allergic reactions such as rash or angioedema.

Before initiating therapy, clinicians should consider several safety aspects.

• Baseline heart rate assessment: ensure resting rate is ≥ 60 bpm.
• Concomitant heart‑rate‑lowering agents: avoid excessive bradycardia when combined with beta‑blockers or digoxin.
• Severe hepatic impairment: use with caution, dose adjustment may be required.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Strong CYP3A4 inhibitors: monitor for increased plasma concentrations.
• Store at ambient temperature: keep in original pack, protect from moisture.

Ivabradine may interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine levels.
• Co‑administration with other heart‑rate‑lowering agents (e.g., beta‑blockers, digoxin): risk of profound bradycardia.
• Other If channel blockers: additive effect on heart rate.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): require heart‑rate monitoring.
• Antihypertensive drugs: may enhance blood‑pressure‑lowering effect.
• CYP3A4 inducers (e.g., rifampicin): may reduce ivabradine efficacy.